The Phase II cut in Alzheimer’s puts a question mark against the lofty heights J&J had envisaged for seltorexant. Less than a ...

Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field. | Johnson ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on September 26. Uy Ear has given his ...

Indeed, the Patient Odyssey Survey II conducted by the Restless Legs Syndrome Foundation in 2022 found RLS significantly ...

Analyst Douglas Tsao from H.C. Wainwright maintained a Hold rating on Alkermes (ALKS – Research Report) and keeping the price target at ...

It’s midnight, and we really should turn off our phones and go to bed, but we can’t stop “doomscrolling” through news apps ...

Centessa Pharmaceuticals plc recently detailed the discovery and preclinical characterization of a novel potent and selective orexin OX2 receptor agonist, ORX-142.

GlobalData’s report assesses the drugs in the Hypocretin Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

The researchers found that a separate chemical messenger, orexin B, does the same in men and male mice. Testosterone, meanwhile, seems to inhibit pain in both sexes. And research indicates it ...

The effects of sleep deprivation on cognitive function may be reversed by treatment with a compound called orexin-A, which occurs naturally in the mammalian brain. The new research was done with ...

周一，H.C. Wainwright对Alkermes（NASDAQ: ALKS）股票维持中性评级，目标价保持在37.00美元不变。在Alkermes介绍其orexin产品组合策略的分析师会议后，该公司对Alkermes的前景越发乐观。这种兴趣的提升是在公司公布了令人鼓舞的早期1b期数据并将ALKS-2680推进到2期研究之后。 ALKS-2680目前正在研究其治疗1型嗜睡症、2型嗜睡症和特发性嗜 ...

周四，Baird重申了对Alkermes (NASDAQ:ALKS)的"跑赢大市"评级和38.00美元的目标价。这一背书是在Alkermes最近举行的投资者活动之后做出的，该活动回顾了公司的Orexin产品组合战略，强调了orexin类药物在嗜睡症之外多种适应症中的潜力，而嗜睡症目前是其主要研究领域。 该活动展示了orexin类药物的多功能性，表明它可能在多个医疗适应症中显著有效。这一进展凸显了公 ...